Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 147

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 147
---
 contracts, contractual damages, reputational
harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of an entity’s operations

Employees

As of the date of this prospectus,
we have three members of our senior management that are engaged as external service providers and four part-time employees. In addition,
we have three part-time personnel engaged in research and development. We are not bound by any collective bargaining agreements. We consider
the relationship with our employees to be good. We also use outside consultants and contractors with special expertise and skills for
limited engagements, including manufacturing and quality assurance. We plan to contract with a contract research organization that
is knowledgeable and experienced in developing, testing and commercializing medical solutions.

<div align='center'>89</div>

Facilities

We do not have manufacturing
facilities. We operate out of our offices in Herzliya 4676652, Israel that are being provided for a monthly fee of $5,500 (including
$3,000 for administrative expenses). We expect to lease additional space as we expand the team upon conclusion of this offering.

Legal Proceedings

CSL Behring GmbH Payment Dispute

In 2019, a controversy has
arisen between us and CSL whether certain unshipped minimum purchase commitments for fibrinogen from 2018 to 2020 are to be paid by us
pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, by and between the Company and CSL, whereby
CSL agreed to supply the Company with fibrinogen. On January 14, 2020, we received a termination letter, or CSL Termination Letter. In
the CSL Termination Letter, CSL demanded a total amount of $820,000, claiming it was owed the minimum purchase commitment amounts under
the Framework Supply Agreement not paid by the Company in 2018 and 2019. In a subsequent correspondence, CSL additionally demanded interest
and damages for lost profit, with an aggregate demand amount of $1,476,382.36. The Company has disputed CSL’s payment demand and
contends that CSL’s demands are baseless under the Framework Supply Agreement, as the minimum purchase commitment under the Framework
Supply Agreement is conditional upon first obtaining approval of the FDA and the European Medicines Evaluation Agency, or EMEA, and other
quality and clinical milestones, none of which has occurred. Notwithstanding, CSL claimed to have obtained a valid German court order
in